17α-hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2828-2836

  Bruno, Robert D ^a   Gover, Tony D ^a   Burger, Angelika M ^a,b   Brodie, Angela M ^a,b   Njar, Vincent C O ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; CALCIUM; CYCLIN D1; CYCLIN E; CYTOCHROME P450 17; ENZYME INHIBITOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MESSENGER RNA; PROTEIN S 100; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; THAPSIGARGIN; UNCLASSIFIED DRUG; VN 124 1; VN 125 1; VN 63 1; VN 85 1; 3 HYDROXY 17 (1H BENZIMIDAZOLE 1 YL)ANDROSTA 5,16 DIENE; 3-HYDROXY-17-(1H-BENZIMIDAZOLE-1-YL)ANDROSTA-5,16-DIENE; ANDROSTANE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CELL CYCLE PROTEIN; INITIATION FACTOR 2;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRESS; UPREGULATION; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR GENE;

ANDROGENS; ANDROSTADIENES; ANIMALS; BENZIMIDAZOLES; CALCIUM; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; EUKARYOTIC INITIATION FACTOR-2; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; THAPSIGARGIN; UP-REGULATION;

EID: 54049128964     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0336     Document Type: Article

References (45)

1. ACS. Cancer Facts and Figures 2008. Atlanta: American Cancer Society; 2008.
2. McConnell JD. Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am 1991;18:1-13.
3. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
4. Fuse H, Korenaga S, Sakari M, et al. Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression. Prostate 2007;67:630-7.
5. Hall PF. Cytochrome P-450 C21scc: one enzyme with two actions: hydroxylase and lyase. J Steroid Biochem Mol Biol 1991;40:527-32.
6. Small EJ, Baron AD, Fippin L, Apodaca D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157:1204-7.
7. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. J Urol 1983;130:152-3.
8. Reid AHM, Attard G, Molife R, et al. Abiraterone, an oral, irreversible CYP450c17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer patients. 98th Annual Meeting for American Association for Cancer Research; 2007 April 17; Los Angeles, CA; 2007.
9. Attard G, Reid AHM, Barrett M, et al. Inhibition of androgen synthesis results in a high response rate in castration refractory prostate cancer. 98th Annual Meeting for American Association for Cancer Research; 2007 April 17; Los Angeles, CA; 2007.
10. Njar VC, Brodie AM. Inhibitors of 17α-hydroxylase/17,20-lyase (CYP17): potential agents for the treatment of prostate cancer. Curr Pharm Des 1999;5:163-80.
11. Handratta VD, Vasaitis TS, Njar VC, et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 2005;48:2972-84.
12. Perkins LM, Payne AH. Quantification of P450scc, P450(17) a, and iron sulfur protein reductase in Leydig cells and adrenals of inbred strains of mice. Endocrinology 1988;123:2675-82.
13. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999;13:1211-33.
14. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000;101:451-4.
15. Liu H, Bowes RC III, van de Water B, Sillence C, Nagelkerke JF, Stevens JL. Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. J Biol Chem 1997;272:21751-9.
16. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999;397:271-4.
17. Shi Y, Vattem KM, Sood R, et al. Identification and characterization of pancreatic eukaryotic initiation factor 2 α-subunit kinase, PEK, involved in translational control. Mol Cell Biol 1998;18:7499-509.
18. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 2004;23:3180-8.
19. Aktas H, Fluckiger R, Acosta JA, Savage JM, Palakurthi SS, Halperin JA. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci U S A 1998;95:8280-5.
20. Lai E, Teodoro T, Volchuk A. Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology 2007;22:193-201.
21. Prostko CR, Brostrom MA, Brostrom CO. Reversible phosphorylation of eukaryotic initiation factor 2α in response to endoplasmic reticular signaling. Mol Cell Biochem 1993;127-128:255-65.
22. Ron D. Translational control in the endoplasmic reticulum stress response. J Clin Invest 2002;110:1383-8.
23. Zinszner H, Kuroda M, Wang X, et al. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998;12:982-95.
24. Palakurthi SS, Fluckiger R, Aktas H, et al. Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res 2000;60:2919-25.
25. Sun S, Han J, Ralph WM, Jr., et al. Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperones 2004;9:76-87.
26. Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 2007;67:1262-9.
27. Pyrko P, Kardosh A, Liu YT, et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 2007;6:1262-75.
28. Njar VC, Kato K, Nnane IP, Grigoryev DN, Long BJ, Brodie AM. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 α-hydroxylase-C17,20-lyase (P450(17) α): potential agents for the treatment of prostate cancer. J Med Chem 1998;41:902-12.
29. Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995;38:2463-71.
30. Potter GA, Hardcastle IR, Jarman M. A Convenient, Large-Scale Synthesis of Abiraterone Acetate [β-Acetoxy-17-(3-pyridyl)androsta-5,16-dien], A Potential New Drug for the Treatment of Prostate Cancer. Organic Preperations and Procedures Int 1997;29:123-34.
31. Patel JB, Huynh CK, Handratta VD, et al. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J Med Chem 2004;47:6716-29.
32. Chou TC, Tan QH, Sirotnak FM. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 1993;31:259-64.
33. Khandelwal A, Gediya LK, Njar VC. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer 2008;98:1234-43.
34. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-50.
35. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 1998;17:361-71.
36. Lecca MR, Wagner U, Patrignani A, Berger EG, Hennet T. Genome-wide analysis of the unfolded protein response in fibroblasts from congenital disorders of glycosylation type-I patients. FASEB J 2005;19:240-2.
37. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059-65.
38. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
39. Jiang F, Shults K, Flye L, et al. S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents. Leuk Res 2005;29:1181-90.
40. Shyu RY, Huang SL, Jiang SY. Retinoic acid increases expression of the calcium-binding protein S100P in human gastric cancer cells. J Biomed Sci 2003;10:313-9.
41. Lukas J, Herzinger T, Hansen K, et al. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 1997;11:1479-92.
42. Savino JA III, Evans JF, Rabinowitz D, Auborn KJ, Carter TH. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol Cancer Ther 2006;5:556-63.
43. Zhang Y, Soboloff J, Zhu Z, Berger SA. Inhibition of Ca2+ influx is required for mitochondrial reactive oxygen species-induced endoplasmic reticulum Ca2+ depletion and cell death in leukemia cells. Mol Pharmacol 2006;70:1424-34.
44. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17β-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90:2317-25.
45. Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007;67:10631-4.